Cell-specific and endothelium-dependent regulations of matrix metalloproteinase-2 in rat aorta

Basic Res Cardiol. 2014 Jul;109(4):419. doi: 10.1007/s00395-014-0419-8. Epub 2014 Jun 8.

Abstract

Chronic activation of angiotensin II (ANGII) and matrix metalloproteinase-2 (MMP-2) during hypertension contributes to increased aortic stiffness. We studied signalling mechanisms employed by ANGII in the regulation of latent (pro-) and active forms of MMP-2 in rat aortic endothelial and smooth muscle cells, along with isolated rat aorta. Using western blotting, we demonstrate that ANGII (1 µmol/L) significantly (P < 0.01) increases pro-MMP-2 protein expression after 8 h not only in endothelial and smooth muscle cells, but also in isolated rat aorta. We demonstrate that ANGII acts via AT1 receptor-activated cell-specific pathways. In endothelial cells, the JNK1/c-jun pathway is activated, whereas in smooth muscle cells, the JAK2/STAT3 pathway. Activation of JAK2/STAT3 pathway in response to ANGII was EGF receptor-dependent. Results obtained in cell culture are in agreement with the results obtained in isolated aorta. However, active MMP-2 was not found under cell culture conditions, whereas in isolated aorta, active MMP-2 was significantly (P < 0.05) increased after stimulation with ANGII, as detected by gelatine zymography. This increase of MMP-2 activity was not inhibited by blocking the pathways we identified to control pro-MMP-2 protein expression, but was abolished in the absence of endothelium. Our findings demonstrate that ANGII regulates pro-MMP-2 protein expression via cell-specific pathways in rat aorta. The endothelium may play an essential role in the activation of pro-MMP-2. These results may lead to new strategies for inhibiting MMP-2 expression and activity in distinct cell types of the aortic wall.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / pharmacology
  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Animals
  • Aorta / drug effects
  • Aorta / enzymology
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Endothelial Cells / drug effects
  • Endothelial Cells / enzymology*
  • Enzyme Activation
  • Enzyme Precursors / metabolism*
  • ErbB Receptors / metabolism
  • Gelatinases / metabolism*
  • Janus Kinase 2 / metabolism
  • Male
  • Matrix Metalloproteinase 2 / metabolism*
  • Mitogen-Activated Protein Kinase 8 / metabolism
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / enzymology*
  • Myocytes, Smooth Muscle / drug effects
  • Myocytes, Smooth Muscle / enzymology*
  • Proto-Oncogene Proteins c-jun / metabolism
  • Rats, Inbred WKY
  • Receptor, Angiotensin, Type 1 / metabolism
  • STAT3 Transcription Factor / metabolism
  • Signal Transduction
  • Time Factors
  • Up-Regulation

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Enzyme Precursors
  • Proto-Oncogene Proteins c-jun
  • Receptor, Angiotensin, Type 1
  • STAT3 Transcription Factor
  • Stat3 protein, rat
  • Angiotensin II
  • Egfr protein, rat
  • ErbB Receptors
  • Jak2 protein, rat
  • Janus Kinase 2
  • Mitogen-Activated Protein Kinase 8
  • Gelatinases
  • progelatinase
  • Matrix Metalloproteinase 2
  • Mmp2 protein, rat